Fig. 8
From: Cancer nanomedicine: a review of recent success in drug delivery
(Reproduced with permission from [69])
The Kaplan–Meier estimates of overall and progression-free survival (a, b respectively) in the intent-to-treat population for liposomal irinotecan (PEP02), irinotecan, and docetaxal